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Abstract 
The problem of medication pricing and lobbying in the healthcare industry has caused 
millions of people within the United States to not be able to afford medications essential to their 
lives. Pharmaceutical companies are taking advantage of the need people have for certain drugs 
by setting the sale price far higher than it costs to produce. My suggested solution is to make 
lobbying illegal in the United States so that pharmaceutical companies would not have control 
over government officials who pass laws to help or hurt the issue of medication pricing. 
Illegalizing government lobbying will take away the incentive politicians have to be biased 
toward a particular party, issue, or industry and will encourage those who get into politics to do 
what is right and not what lines their pockets. With my suggested solution, laws regarding price 
ceilings would be able to be passed more easily, thus allowing more of the American population 
to be able to afford their medication. This essential change would enable the United States to 
become one step closer to stop saving the rich. 
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The cost of healthcare occupies political debate tables in many countries around the 
world. Specifically, the cost of medication is one of the hot button issues, due to the varied 
ideals. Some countries have higher taxes, allowing consumer upfront costs to be lower at a 
doctor's office or pharmacy, whereas some countries are charged an obscene amount for them or 
do not have access to these drugs at all. The United States hovers somewhere in the middle of 
this spectrum. Citizens have access to various types of medication, but to physically attain them 
is a monstrous struggle. Medications are seemingly unattainable due to the outrageous initial cost 
before the customer’s insurance is processed. Even when the insurance covers the medication, 
the out-of-pocket cost can be sums of $6,650 per year or higher when a customer is taking a 
regular dose of a crucial medication (Clarkin 2019).  The medications that are most essential to 
living are the most in demand and therefore are going for the highest prices. Medications such as 
Eliquis and Wixela are prime examples of high demand medications. Eliquis is a blood thinner 
that is commonly prescribed to patients experiencing clotting disorders. On the Eliquis website, 
their out-of-pocket price is displayed at an outrageous $500 per month. A medication of this kind 
is essential to people who suffer from a common diagnosis of high blood pressure, and without it 
will suffer the deadly consequences. Wixela is a generic asthma inhaler that is commonly 
prescribed to school aged children. Coupons that are redeemable at the most popular pharmacies 
such as CVS and Walgreens for only one Wixela inhaler bring the price down to a minimum of 
$253.94 according to the commonly used Rx coupon website, Goodrx.com. Many Americans are 
living paycheck to paycheck. They work just to keep food on their tables and a roof over their 
heads. Providing the essentials is hard enough just to be compounded with paying hundreds of 
dollars for medications makes it virtually impossible to have it all. Medication that people need 
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to survive should be set at a price that Americans can afford. You should not have to be rich to 
live. 
The pricing of pharmaceutical medication is, to a certain degree, a legal monopoly. When 
a company is first to discover a drug that works for a specific health problem, that company 
patents it. Stopfakes.com states that a patent allows companies to have exclusive selling rights to 
this drug for a 20-year time period from when the application of the patent was filed according to 
current U.S mandate. When the patent finally expires, the company who had initially discovered 
the product still can get away with charging unreasonable prices because of the generic product 
being priced at a similar or the same price as the brand name. Thus, allowing the cost to fluctuate 
with demand and costs of medications that are dire to their intended customers to sky-rocket 
once again (Ching 2000). While this is an advantage for the developer, it leaves their customers 
in a pitfall. When there is only one supplier, a monopoly is created thus forcing consumers to 
buy from the singular distributer, sky-rocketing the demand. With the monopolizing power in the 
provider’s hands, they can set the price at whatever they choose. Consumers are forced to pay 
astronomical prices for medications that are essential to their quality of life. The paradox this has 
created in recent years has sparked conversations about instituting a concept that would restrict 
companies from outrageous pricing. Although patents are a great incentive for researchers to find 
progressive cures, adding restrictive measures would allow the inventors to make money while 
decreasing the negative side effects on consumers. The concept is called a price ceiling, meaning 
that there is a limit on how much companies can charge. Polls, research groups, politicians, and 
especially consumers believe that there has to be a change because “patents are a privilege the 
industry has abused.” (Al-Sibai 2020). While the introduction of patents was intended to protect 
the companies' rights to own their original knowledge, the negative side effect of patents allow 
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companies to value that knowledge at a tremendous price—thus hurting the people they 
supposedly serve. 
As of right now, there is no forward progress on this paradox. Due to the fact that large 
pharmaceutical companies have notorious connections with people in political power, there is a 
governmental standstill. The corrupt connection is a product of lobbying, meaning that 
politicians let personal relationships and capital donations affect their judgement. Lobbying is 
one of the reasons why many things are not getting done in the government as quickly as they 
should be, or even being done at all. Susan Scutti references the independent research group, 
OpenSecrets, and identifies that “individual companies within the pharmaceuticals and health 
products sector spent $194.3 million on lobbying as of October 24, 2018 over and above the 
amount disclosed by PhRMA” (Scutti 2019). When the pharmaceutical companies monopolize 
the market, they not only benefit monetarily but economically as well. By bringing in an obscene 
amount of money, the company reinvests it into product research and development, enabling 
them to come out with another new patented drug to continue their monopoly, thus continuing 
their reign over the drug market. As these large companies flood the market with their products, 
they get more capital that they can funnel into political campaigns to help those whose beliefs 
align with their own and will pass laws that help them remain in power. 
A solution that has been suggested by journalists, the public, and some politicians is the 
possibility of putting a limit on what these drugs can cost; this concept is called a price ceiling. 
While this is possible, it is not probable within the current state of the United States government. 
Politicians in the Trump administration including the former President himself were trying to 
implement a ceiling on medication costs in 2019 (Al-Sibai 2020). Unfortunately, divides 
between the American political parties combined with Big Pharma funding political pockets 
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prevented this from being successful. The divided views are fueled by the lobbying by Big 
Pharma for some politicians and not others. Chris McGreal from The Guardian reported that 
politicians high up in the ranks such as Congressmen Mitch McConnell and Tom Marino have 
been linked to generous donations coming from pharmaceutical companies. In fact, Marino went 
as far as to use the donations from these companies to motivate his forging legislation preventing 
stricter opioid distribution rules. The self-interest of politicians is getting in the way of United 
States citizens having reasonably priced essential medication.  
While the idea of a price ceiling is attractive, actually instilling this concept would take a 
multitude of years. To get a bill passed through Congress in conjunction with a significant 
amount of research on individual medication and production costs to be able to set a realistic 
boundary, all the while having politicians funded by the drug industry keeping a careful eye on 
the process make this suggestion improbable while corruption is still running rampant. The 
counter solution that I propose is to make lobbying illegal in the United States before instituting 
a price ceiling. I posit that eliminating lobbying is the best way that we can dismantle the control 
that big pharmaceutical companies have on the government as well as keeping big players in 
other facets of business out of politics in a timelier manner. It would decrease the motivation that 
politicians have right now to cater to these industries because the fiscal advantages would 
dissolve. With lobbying being illegal, the government would be cleaner and less corrupt. Instead 
of having it be funded by industries like pharmaceutical companies with their own interest in 
mind, the government would be able to make less corrupt decisions. Things like ceilings on 
medication prices would then be easily passed, benefitting most of the U.S. population that is 
living paycheck to paycheck.  
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With lobbying illegal, the ceiling would be able to be set at a reasonable amount which 
would still allow pharmaceutical companies to make money while being accessible to the general 
public. The pricing method that would be used could be uniform to all patented medications so it 
would be simple and quick to implement. For example, after conducting research and debating a 
percentage, the selling price could be 20% above the unit cost of manufacturing. If a month's 
supply of a pharmaceutical medication costs $100 to make, package, ship, and sell this is called 
the unit cost of manufacturing. The price ceiling on this particular medication would be 120% of 
the cost which is equal to $120. The price would be able to be easily altered to match the amount 
the consumer is purchasing because of how constant of a method it is, and it would allow 
companies who sell medications that are more expensive to produce to still make a profit that is 
relative to how much goes into production.  
A popular counterargument to why the United States can’t lower drug prices is that drug 
companies will go out of business with lower profit margins and, consequently, cause less 
research and development into new medicines. The reality is, all business start-ups cost initial 
capital. To create an airline company, money needs to be put into the business to buy planes, 
landing strips, airports, and all the training, employment, and maintenance that goes along with 
them all before any profit can be made. An example such as this one could be made with any 
business model in any field in a capitalistic society including the drug manufacturing, 
distribution, or research industries. If an institution isn’t going to put in the initial capital it takes 
to start a business, then the business will never be created. Pfizer is one of the pharmaceutical 
companies that is known for popular medications such as Eliquis, EpiPen, and Neosporin. It is 
the first company to get the FDA approval on their COVID-19 vaccine in late 2020 and its net 
worth is $210 billion dollars as reported by drugwatch.com. To put this number in perspective, 
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Investopedia lists Elon Musk as the richest man in the world with a staggering 2021 net worth of 
$197 billion dollars. Not to mention that Pfizer is one of many pharmaceutical companies that 
are bringing in billions of dollars per year in revenue. These are the kinds of companies that are 
“donating” to politicians to make sure that these revenues are protected at all costs and will be 
able to easily afford to move to my proposed pricing plan while still putting out quality 
medications for those in need. This level of net worth isn’t required to create medications and 
keep their business running.  
A country that has started to reform their healthcare system is our northern neighbor. 
Canada is a prime example of a developed country that has spent much less money on their 
healthcare businesses than the United States, while still allowing their citizens to access the care 
they need. The country spent $1,589 dollars less per capita on healthcare institutions such as 
hospitals and their employees in 2002 and the differences in the administration and salaries were 
the largest with both being more than 30% of a contrast. (Pozen, Cutler 2010) With this data, it 
can be concluded that U.S. healthcare companies have the budget to administer the service they 
currently provide without investing as much in wage expenses. Canada has successfully changed 
the system from giving more of their profits to their employees to giving back to the customers 
they serve. The healthcare industry has begun to rightly prioritize the health of individuals and 
their families rather, a step the United States desperately needs to make. 
The pharmaceutical industry already sits in a powerful position in every country around 
the world. They provide an asset that cannot be replaced and will always be in high demand. In 
the United States, which is viewed as an advanced country, we need to be able to provide 
medicines to those in need--regardless of economic status. These companies are taking 
advantage of the fact that citizens have limited substitutions available for the life-saving drugs 
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they supply. Their vulnerabilities should not be exploited, but rather should be identified and 
collaborated with. Eliminating lobbying will limit corruption between the pharmaceutical 
industry and the government and will allow the government to implement a price ceiling on 
essential medications. This outlaw is the answer to the problem of having Big Pharma control as 
much as it does in our current economy and political system.  
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